RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE. COLLEGEVILLE, Pa., and MANNHEIM, Germany, Feb. 3 /PRNewswire/ -- Poulenc Rorer Inc., (NYSE: RPR) Boehringer Mannheim GmbH and Boehringer Mannheim Pharmaceuticals Corporation announced that they will co-develop and co-market Boehringer Mannheim's third generation bisphosphonate to be used in the treatment of bone metabolism disorders. Development will be targeted for cancer-related hypercalcemia and osteolysis (bone destruction), and simultaneously for osteoporosis. Approval of cancer-related indications will likely precede the osteoporosis indication. It will be jointly marketed world wide, although Japan is not part of the cooperative agreement. According to the agreement, Boehringer Mannheim will perform most of the pre-clinical development of the product as well as some clinical development. RPR will be responsible for the majority of clinical development for the osteoporosis indication. The compound is currently in Phase I trials, and will enter Phase II in the first quarter of 1992. Terms of the agreement and projected sales of the product are not being disclosed. "RPR is pleased with this opportunity to bring additional depth to its global bone metabolism franchise, a key part of its R&D strategy, and to build a long-term relationship with Boehringer Mannheim," said Robert E. Cawthorn, Chairman and Chief Executive Officer, Rhone-Poulenc Rorer. "Their third generation bisphosphonate is one of the best compounds under development at this time. It will be an excellent addition to our product portfolio which includes Calsynar(R)/Calcimar(R) (salmon calcitonin), Bonefos(TM)/Clastoban(TM) (clodronate), and Menorest(TM) an estrogen patch pending approval." "Our collaboration with RPR is a key element in Boehringer Mannheim's U.S. pharmaceutical market entry," said Professor Ulrich Abshagen, Member of the Executive Board, Boehringer Mannheim GmbH. "RPR will be an excellent development and marketing partner on our breakthrough bisphosphonate compound. Their proven expertise in research of bone disease, and particularly osteoporosis, fits well with Boehringer Mannheim's own extensive activities in this field. Equally important to our decision is the complementary position of our sales forces in the European and U.S. markets." Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to human health. It operates in the following major therapeutic areas: cardiovascular medicine; bone metabolism/ rheumatology; gastroenterology; central nervous system/analgesia; infectious diseases/AIDS; oncology; hypersensitivity; and plasma derivatives. RPR had 1991 sales of more than $3.8 billion and research and development spending of more than $440 million. The company operates in all major markets of the world. Boehringer Mannheim Pharmaceuticals Corporation has recently started commercial operations in the U.S. and develops and markets important new therapies for cardiovascular, metabolic and oncologic diseases. Boehringer Mannheim Pharmaceuticals is part of the worldwide operating Boehringer Mannheim Group, which specializes in diagnostics, orthopedics, pharmaceuticals and biochemicals. /delval/ -0- 2/3/92 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or 215-454-3085, or investors relations, 215-454-3851/ CO: Rhone-Poulenc Rorer Inc.; Boehringer Mannheim Pharmaceuticals Corporation ST: Pennsylvania IN: MTC SU: JVN
JS -- PH002 -- 5938 02/03/92 06:30 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 3, 1992|
|Previous Article:||RHONE-POULENC RORER REPORTS DOUBLING IN ANNUAL EARNINGS|
|Next Article:||SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR FEB. 3, 1992|